Is EMR a Buy? What to Consider in 2026
Last updated June 2026
Short answer
There is no universal answer to whether EMR is a buy; it depends on your thesis, time horizon, and what you already own. Below is the case for Emerson Electric, the main risks to weigh, where the stock trades, and a framework to decide for yourself. This is informational, not a recommendation, and Walnut is not an investment adviser.
Emerson Electric is a global industrial-technology company focused on automation, helping manufacturers and process industries run their plants more efficiently, safely, and reliably. Over the past several years Emerson has transformed itself from a diversified industrial conglomerate into a more focused automation pure-play, divesting legacy businesses like its commercial and residential climate-technologies unit and acquiring software and measurement assets. Its core products include process control systems, measurement and analytical instruments, valves and actuators, software for plant operations, and test and measurement equipment, much of it sold under brands like DeltaV, Rosemount, Fisher, AspenTech, and NI (National Instruments). Customers span energy, chemicals, life sciences, power, water, food and beverage, and discrete manufacturing. Emerson makes money by selling this hardware and software plus recurring service, software subscriptions, and aftermarket parts, with a meaningful share of revenue tied to keeping installed systems running. The shift toward higher-margin software and recurring revenue, anchored by its majority stake in AspenTech, is central to its strategy. Emerson is headquartered in St. Louis, Missouri.
The case for Emerson Electric
1. Automation pure-play transformation.
Emerson has reshaped itself into a focused automation company by divesting non-core units and concentrating on process and industrial automation. This sharper portfolio carries higher margins and more secular growth than the old conglomerate, and it positions Emerson as a leading supplier as manufacturers invest to modernize, digitize, and automate their operations.
2. Software and recurring revenue.
Through acquisitions including a majority stake in AspenTech and the NI test-and-measurement business, Emerson is building a larger, higher-margin software and recurring-revenue base. Industrial software for optimization, simulation, and asset management deepens customer relationships and shifts the revenue mix toward stickier, subscription-like streams that command premium valuations.
3. Secular industrial tailwinds.
Reshoring of manufacturing, energy-transition projects, decarbonization, sustainability initiatives, life-sciences capacity, and the buildout of power and data-center infrastructure all drive demand for automation, measurement, and control. Emerson's broad installed base and aftermarket give it recurring exposure to these multi-year capital cycles across diverse end markets.
4. Margins and capital returns.
The focus on automation, software, and operational efficiency supports margin expansion and strong free cash flow. Emerson is a long-standing dividend payer, one of the Dividend Kings with decades of consecutive increases, and complements the dividend with buybacks, returning substantial capital while investing in its higher-growth software and automation portfolio.
The risks to weigh
Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. The transformation through large acquisitions like AspenTech and NI carries integration, execution, and valuation risk, and the company took on debt and complexity to fund deals. Competition in automation and industrial software is intense, including from larger and lower-cost rivals. Foreign-exchange effects, supply-chain disruptions, and project delays can pressure results. The stock can be volatile around portfolio moves and macro cycles, and the payoff from the software pivot must still prove out fully.
Valuation context (as of early 2026)
- Revenue (TTM): ~$17-18 billion
- Operating margin: ~20%+, expanding
- Revenue growth: Mid-single-digit underlying, plus acquisitions
- Software and recurring mix: Growing share of revenue
- P/E (TTM): Above the average industrial
- Dividend yield: Modest, ~1.7%, a Dividend King
- Free cash flow: Strong, high conversion
- Dividend history: Decades of consecutive increases
Emerson trades at a premium to the average industrial, reflecting its transformation into a higher-margin automation and software business and its anchor stake in AspenTech. The market values the recurring-revenue mix, margin expansion, and strong cash generation, while weighing acquisition and integration risk. Its Dividend King status and steady cash flow underpin a quality-industrial profile.
How to decide for yourself
Rather than asking whether EMR is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold EMR indirectly through an index or sector ETF before adding more.
For the full picture, see the EMR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about EMR against your real portfolio and see your actual exposure before deciding.
Build a basket around EMR with Walnut
Use Emerson Electric as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is EMR a good stock to buy right now?
+
There is no universal answer. Whether Emerson Electric fits depends on your thesis, time horizon, risk tolerance, and what you already own. This page lays out the case for, the main risks, and where the stock trades, so you can decide for yourself. Walnut is not an investment adviser and this is not a recommendation.
What does Emerson Electric do?
+
Automation-technology leader shifting toward higher-margin industrial software and recurring revenue, a Dividend King.
What are the main risks of EMR?
+
Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. The transformation through large acquisitions like AspenTech and NI carries integration, execution, and valuation risk, and the company took on debt and complexity to fund deals. Competition in automation and industrial software is intense, including from larger and lower-cost rivals. Foreign-exchange effects, supply-chain disruptions, and project delays can pressure results. The stock can be volatile around portfolio moves and macro cycles, and the payoff from the software pivot must still prove out fully.
What is EMR's ticker symbol?
+
EMR, listed on the NYSE. Officially Emerson Electric Co., headquartered in St. Louis, Missouri. It trades during US market hours.
What does Emerson Electric do?
+
Emerson is a global automation-technology company that helps manufacturers and process industries run plants efficiently and safely. It makes control systems, measurement and analytical instruments, valves, and industrial software under brands like DeltaV, Rosemount, Fisher, AspenTech, and NI, plus recurring service and software.
Who are Emerson's main competitors?
+
In automation it competes with Siemens, ABB, Schneider Electric, Honeywell, Rockwell Automation, and Yokogawa. In industrial software it competes with AVEVA and Siemens Digital Industries, and in test and measurement, through NI, with Keysight, Tektronix, and Advantest.
Is Emerson an industrial stock?
+
Yes. Emerson is an industrial-technology company focused on automation. It has transformed from a diversified industrial conglomerate into a more focused automation and industrial-software pure-play, but it remains classified within the industrials sector.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell EMR; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.